Tisol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tisol

This foundational section defines the medicine Tisol, its composition, classification, and general purpose, strictly avoiding dosage, usage instructions, specific indications, warnings, or commercial details.

Property Description
Active ingredient Ofloxacin
Form Tablets, Ophthalmic Solution, Otic Solution
Pharmacological class Fluoroquinolone (Antibacterial agent)
Common use Treatment of bacterial infections
Origin Synthetic

What Type of Medicine is Tisol and What is its Composition?

Tisol is a prescription-only medicine whose single active component is the chemically synthesized compound, Ofloxacin. It is classified as a fluoroquinolone antibiotic, a designation that places it within a powerful family of synthetic broad-spectrum antibacterial agents. Ofloxacin is indicated for use against a range of susceptible bacterial strains. The medicine’s primary therapeutic role is to provide systemic or local treatment against specific microbial pathogens.

Tisol is a single-ingredient product, containing only Ofloxacin for its therapeutic effect. The brand is characteristically available in versatile dosage forms suited for different administration routes, including tablets for internal (oral) use and specialized, typically buffered, ophthalmic solutions or otic solutions for direct topical application. This manufacturing flexibility allows the Ofloxacin component to be delivered to either the body's systems or a localized infection site, such as in the case of a bacterial ear infection.


The Core Purpose: Tisol's Bactericidal Action

The fundamental general purpose of Tisol is to provide a bactericidal effect, meaning it actively kills the harmful bacteria causing an infection, rather than merely halting their multiplication. Ofloxacin disrupts bacterial DNA gyrase and topoisomerase IV, two enzymes essential for bacterial genetic replication and survival. This mechanism of action results in the elimination of the microbial population. This method helps clear infections by targeting the bacteria's essential reproductive machinery, thereby serving as a therapeutic tool against established bacterial threats.

Regulatory References

  1. EMA review of fluoroquinolone side effects (includes Ofloxacin)
  2. Ofloxacin - StatPearls - NCBI Bookshelf (Mechanism and Indications)

What side effects are possible with Tisol?

Possible side effects and safety information

The safety profile of Tisol (Ofloxacin) is formally documented in government regulatory sources, which classify adverse reactions based on the physiological systems affected and their frequency in clinical use. These documented events establish the medicine's risk profile without offering clinical advice.

Adverse Reaction Classifications

Adverse effects are grouped by System-Organ Class, affecting the Gastrointestinal (e.g., nausea, diarrhea) and Nervous Systems (e.g., headache, dizziness, insomnia) most commonly. Rare effects include serious reactions such as tendinitis and psychiatric disturbances. The potential for photosensitivity (increased skin sensitivity to light) is also noted.

Serious Safety Concerns

Official regulatory documents emphasize the potential for serious, disabling, and potentially irreversible adverse reactions associated with systemic use. These include damage to the tendons (e.g., tendon rupture), the peripheral nerves (peripheral neuropathy), and the central nervous system. Other serious documented risks involve hypersensitivity reactions, hepatic necrosis/failure, and rare cardiac rhythm changes (e.g., QT interval prolongation).

Population and Exposure-Related Notes

Specific populations are documented as having heightened risk for certain effects. Older adults and individuals using concurrent corticosteroids are noted to have an increased risk of tendon damage. Tendinitis and tendon rupture may occur during treatment or with a delayed onset of up to several months after therapy has ended. Caution is also advised regarding the use of Tisol in patients with pre-existing conditions like myasthenia gravis due to potential for exacerbation.

Overdose and Emergency Response

An overdose of Tisol is a medical emergency that requires immediate clinical intervention. Official regulatory information describes that an overdosage can lead to a range of signs, symptoms, and laboratory findings, including potential complications such as organ toxicity or delayed metabolic issues. The required clinical response is based on the severity of the exposure, which can range from symptomatic presentation to a life-threatening event.

When to Seek Immediate Medical Help

Always seek urgent medical attention by calling emergency services if you suspect an overdose of Tisol has occurred, or if an individual shows signs of severe intoxication or distress. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) documentation outlines that medical personnel should be prepared to monitor vital signs, assess for organ complications, and employ specific treatment procedures, including the use of any listed antidotes, to manage the acute toxic effects.

Overdose risk factors considered in regulatory review include the amount of drug consumed in a single event, which is categorized based on whether it is associated with symptoms or is likely to be life-threatening. Treatment focuses on supportive care and reducing systemic exposure, such as through activated charcoal administration or specific reversal agents, where applicable, to ensure patient recovery.

Therapeutic Uses of Tisol

What Tisol Treats: Main Uses and Benefits

Tisol is used to manage bacterial infections across various body systems. It is used to help with a range of conditions and may assist with easing the symptom burden associated with bacterial pathogens.

Tisol is commonly used across conditions presenting with acute episodes that affect the lower respiratory tract (pneumonia, acute bronchitis exacerbations), the urogenital system (complicated UTIs, prostatitis, PID), and surface areas like the eye and ear (conjunctivitis, otitis externa). Tisol is relevant for managing symptoms related to systemic imbalance (such as fever) and localized discomfort (like pain or discharge).

“Tisol supports the patient during difficult episodes by easing distress associated with severe or disruptive infections.”

This therapeutic focus is relevant for easing symptoms that create noticeable functional strain or interfere with daily stability. The topical application offers symptomatic relief that helps patients cope more steadily with acute localized symptoms.


Quick Fact: Relief for Systemic and Localized Discomfort Tisol is used across therapeutic domains involving heightened symptoms, assisting with the management of both internal fever and external ear/eye pain.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

This section outlines the official population eligibility and exclusion criteria for TIROSINT-SOL (levothyroxine sodium) based strictly on government regulatory documents.

Populations Excluded or Restricted from Use

Classification Who Must Not Use the Medicine (Contraindications)
Adrenal/Thyroid Status Patients with uncorrected adrenal insufficiency (requires prior glucocorticoid treatment).
Patients with untreated thyrotoxicosis or acute myocardial infarction.
Hypersensitivity Patients with known hypersensitivity to levothyroxine sodium or the excipient glycerol.

Populations Requiring Special Consideration or Restriction

Classification Who Requires Conditional Use (Warnings/Precautions)
Age and Heart Health Elderly patients and those with underlying cardiovascular disease must be started at a lower initial dose due to the increased risk of cardiac adverse reactions.
Other Conditions Patients with diabetes mellitus may experience worsening of glycemic control, requiring careful monitoring.
Limitations of Use The medicine must not be used for weight loss or obesity treatment in patients with normal thyroid function. It is also not indicated for temporary hypothyroidism during recovery from subacute thyroiditis.

Eligible Populations

The product is officially indicated for use as replacement therapy in all forms of congenital or acquired hypothyroidism across adult and pediatric patients, including neonates. Use during pregnancy and lactation is generally acceptable, though dosage adjustments are often necessary during and immediately after pregnancy to maintain adequate thyroid levels.

What should I know about interactions with other medicines?

Tisol Interactions with other medicines and products

The official regulatory profile for Tisol (Ofloxacin) highlights specific constraints based on its chemical properties and physiological effects, structured around absorption and additive risk.

Exposure-Altering Interactions (Reduced Absorption)

Co-administration with preparations containing polyvalent metal cations (such as Antacids with Aluminum or Magnesium, Sucralfate, and Iron/Zinc supplements) significantly reduces the absorption of Tisol, decreasing its systemic exposure. Regulatory labeling requires that Tisol must not be taken within the two-hour period before or the two-hour period after these products to minimize this interference.

Pharmacodynamic Interactions (Additive Risk)

  • QT Prolonging Agents: Tisol must be used with caution alongside medicines known to prolong the QT interval (e.g., specific antiarrhythmics, macrolides) due to an increased risk of cardiac rhythm changes.
  • CNS Agents: The use of Tisol with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Fenbufen, may contribute to a pronounced lowering of the cerebral seizure threshold.
  • Corticosteroids: A documented pharmacodynamic interaction exists with Corticosteroids that increases the risk of tendinitis and tendon rupture, particularly noted in elderly populations.
  • Other Agents: Tisol may potentiate the effects of Oral Hypoglycemic Agents (like Glibenclamide) and Vitamin K Antagonists (like Warfarin), requiring careful monitoring of their therapeutic effects.

Clearance Modification

Renal clearance of Tisol may be reduced by products that inhibit tubular secretion, such as Probenecid, resulting in higher plasma concentrations.

Mechanism of Action

How Tisol Works

The mechanism of action for Tisol (Ofloxacin) is centered on its highly specific, bactericidal action against the core processes of bacterial DNA management.


Targeted Inhibition of Bacterial DNA Management

Tisol acts by directly engaging the core processes of bacterial DNA management, employing a mechanism unique to its class. The drug's primary biological targets are two essential bacterial enzymes, DNA Gyrase (Topoisomerase II) and Topoisomerase IV, which are responsible for managing the structure and separation of the bacterial genome. By inhibiting the function of these enzymes, Ofloxacin stabilizes cleaved DNA strands, leading to overwhelming genomic stress and preventing the cell from completing replication or division.


Cascade Leading to Rapid Microbial Elimination

The molecular inhibition triggers an irreversible mechanistic cascade within the pathogen. The accumulation of irreparable DNA double-strand breaks and the physical halting of cell division result in the immediate and active death of the bacterial cell—a bactericidal effect. The direct destruction of the pathogen results in a reduction of the microbial load, which is the fundamental physiological consequence of reducing the pathogenic microbial population.


️ Mechanisms Limiting Effectiveness

The mechanism's success is constrained by bacterial resistance. The most common limitations are the development of mutations in the target enzyme genes (gyrA and parC) that reduce Ofloxacin's physical binding affinity, and the presence of bacterial efflux pumps that actively expel the drug molecule from the cell. In these scenarios, the drug fails to reach the necessary inhibitory concentration, thereby preventing the core physiological killing effect.

Dosage and Administration Information

Tisol is administered through distinct routes based on the required therapeutic reach: oral or intravenous for systemic effect, and topical for localized effect using the specialized ophthalmic or otic solutions. The systemic use protocol defines an adult daily dosing regimen typically ranging from 200 mg up to a maximum of 800 mg. Doses higher than 400 mg must be divided and administered twice daily, and it is permitted for the tablet to be taken either with or without food.

However, the oral administration must be separated by at least two hours from the intake of products containing mineral ions, such as antacids or iron supplements, as these agents significantly reduce absorption. The standard duration for systemic therapy is generally short, ranging from 3 to 14 days, though prolonged courses are documented, with the recommendation that total systemic treatment should not exceed two months.

The usage protocol includes dose adjustments for patients with reduced renal function (creatinine clearance < 50 mL/min) or severe hepatic impairment. Crucially, the systemic medication is contraindicated for use in children and growing adolescents. The topical ophthalmic solution is exempt from this restriction and is used in children one year of age and older.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tisol (Ofloxacin)

This section summarizes the high-level evidence landscape for the active ingredient in Tisol, Ofloxacin, focusing only on findings from controlled clinical trials and authoritative scientific reviews. It describes the types of research that exist, the populations studied, and what the research examined, without offering clinical guidance or interpretation of results.

Evidence Supporting Systemic Use in Major Infections

Research examining the use of Tisol for infections across body systems is largely based on controlled clinical trials and multicenter studies. For Lower Respiratory Tract Infections (such as pneumonia or acute bronchitis exacerbations), studies explored how the rates of clinical response and bacterial clearance were observed against other study arms. Research describes patterns where eradication rates were noted in the observed populations, while evidence related to overall long-term survival measures remains limited.

For Urinary Tract Infections (UTIs), particularly complicated infections and prostatitis, numerous comparative controlled trials monitored the rate of microbiological cure and the rate of clinical cure (resolution of symptoms like localized pain). Research has explored the outcomes related to bacterial clearance in complicated infections. Post-marketing observations, which do not assess efficacy, have focused on the need to monitor for antimicrobial resistance patterns, particularly concerning the study of uncomplicated UTIs.

Evidence from Topical Research for Eye and Ear Infections

For conditions like bacterial conjunctivitis and infections of the external or middle ear, the evidence comes from numerous, short-term, localized controlled trials. In both ophthalmic (eye) and otic (ear) research, studies monitored the rate of clinical cure and microbiological eradication over very short treatment courses. The research describes patterns observed where clearance and bacterial eradication were measured in the observed populations, consistent with other topical antibacterial solutions. Studies evaluated the use of the topical solution across a broad age range, including children.

Key Evidence Gaps and Areas of Uncertainty

A major area of uncertainty is the ongoing global monitoring of bacterial resistance patterns. Research is ongoing, and post-marketing surveillance continues to monitor how outcomes related to acute clearance may be influenced by evolving resistance patterns. Long-term effects are not fully established for most indications, meaning the available data is largely derived from the acute phases of infection. Additionally, data for certain complicated groups remain insufficient, and results apply mainly to the populations studied in the primary trials.

Key Studies & References NIH StatPearls: Ofloxacin

Frequently Asked Questions (FAQ)

Common questions about Tisol (FAQ)


Q: Is Tisol the same kind of medicine as [similar drug name]?

A: Tisol is the brand name for the generic medicine Ofloxacin, which is classified as a fluoroquinolone antibiotic. This classification defines the drug as a synthetic, broad-spectrum antibacterial agent. While other drugs may treat similar infections, their specific chemical structures and effects may vary.


Q: Do I need to change my diet while taking Tisol?

A: Official information states that the oral form of Tisol can be taken with or without food. However, regulatory documents require that the medicine must be taken at least two hours before or two hours after consuming antacids or supplements that contain polyvalent metal ions (e.g., calcium, iron, or zinc), as these can significantly reduce the medicine’s absorption. Patients are generally advised to consult a healthcare provider for specific dietary guidance.


Q: What does 'contraindicated' mean for Tisol?

A: A 'contraindication' is a term used in official regulatory documents to describe a condition where the use of a medicine is not recommended because the risk of harm clearly outweighs any potential benefit. For Tisol, its use in certain populations, such as growing adolescents, is officially listed as contraindicated.


Q: What is the difference between Tisol and its generic version?

A: Tisol is the brand name chosen by the manufacturer, and its active ingredient is Ofloxacin. The generic version is simply called Ofloxacin. Both the brand name and the generic contain the exact same active component and are regulated to meet the same quality and efficacy standards as the brand name drug.


Q: Is it normal for the side effects of Tisol to go away after a few weeks?

A: Official safety warnings note that some serious adverse reactions associated with this class of medicine, such as peripheral neuropathy (nerve damage) and tendon damage, can have a delayed onset or continue for long periods after the medicine is stopped. Any side effect that is severe, unusual, or persistent should be reported to a healthcare provider for evaluation.


Q: What kind of monitoring is needed while taking Tisol?

A: Official guidelines mention that a healthcare provider may need to perform specific monitoring, such as blood and urine tests, while the patient is using the medicine. Monitoring is also particularly noted when Tisol is used alongside other agents, such as warfarin or certain diabetes medications, that may require careful monitoring of the patient's condition.


Q: How is Tisol processed by the liver?

A: Pharmacological data from official sources indicates that Tisol is eliminated primarily by the kidneys, with 65% to 80% of the dose excreted unchanged. Pharmacokinetic data suggests the liver's involvement in processing is small, as the drug is mainly eliminated through the kidneys. However, dose adjustments are still required for patients who have severe hepatic (liver) impairment.


Q: What are the signs of a serious allergic reaction to Tisol?

A: Official safety documents advise that signs of a serious allergic reaction require immediate medical attention. These signs can include hives, swelling of the lips, tongue, or face, difficulty breathing or swallowing, throat tightness, rapid heartbeat, or feeling faint.


Q: What happens if I miss a dose of Tisol?

A: Official guidance states that instructions for a missed dose depend on the prescribed schedule; generally, a missed dose is either taken as soon as possible, or skipped entirely if it is almost time for the next dose, according to the schedule provided by the prescriber. Extra medicine should not be taken to make up for a missed dose.


Q: What should I do if I feel dizzy after starting Tisol?

A: Dizziness is officially listed as a common adverse effect, as it can affect the central nervous system. Official labeling generally advises patients to avoid driving or operating machinery until they know how the medicine affects them. Patients are advised to contact a healthcare provider if dizziness becomes severe or persistent.


Q: How quickly does Tisol begin to show an effect?

A: Official patient information for the otic (ear drop) form notes that symptoms should generally begin to improve within the first few days of treatment. Patients are advised to contact their healthcare provider if symptoms do not improve or if they worsen during treatment.


Q: What kinds of tests might a doctor do before prescribing Tisol?

A: Official information mentions that pre-existing conditions like reduced kidney or liver function require dose adjustments, which indicates that the monitoring of these conditions may be necessary. Blood and urine tests are also noted to be needed during the course of treatment to check for unwanted effects.


Q: Can I take Tisol if I am pregnant or planning to be?

A: Official documents state that the use of Tisol during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus, as animal studies have shown potential adverse effects. The medicine may appear in breastmilk in low levels, and its use during breastfeeding is generally acceptable with monitoring of the infant.


Q: What happens if I stop taking Tisol suddenly?

A: Official information warns that stopping the medicine too soon or skipping doses may result in the infection not being completely treated, which can lead to bacterial resistance. Separately, official safety warnings advise immediate cessation if certain serious adverse effects occur, such as tendon pain. Any changes to the medication schedule should be discussed with a healthcare provider.


Q: What does the drug label say about using Tisol with herbal remedies?

A: The drug label emphasizes avoiding products containing polyvalent minerals, which may be present in certain supplements or herbal remedies, due to reduced absorption. Official patient information advises patients to notify a healthcare provider about any non-prescription medications, supplements, or herbal products they are using.


Q: Does Tisol show up on a standard drug test?

A: Official labeling has noted that this medicine may cause false-positive urine screening results for opiates when testing is done with certain commercially available kits. If a positive result occurs, official guidance suggests confirmation with a more specific, non-immunoassay test.


Q: What if Tisol doesn't seem to be working for me after the expected time?

A: Official patient guidance advises consulting with a healthcare provider if symptoms do not improve within a few days or if they get worse during treatment. This consultation is necessary to determine if the infection is resistant or if an alternative medicine is required.


Q: What is the half-life of Tisol?

A: Pharmacological data in regulatory documents indicates that the plasma elimination half-life of the active ingredient, Ofloxacin, is approximately 5 to 8 hours in young, healthy adults. This measure is used by prescribers to understand how quickly the medicine is cleared from the body.

How should Tisol be stored and disposed of?

How to Store and Dispose of Tisol? (Ofloxacin)

The storage and disposal of Tisol (Ofloxacin) must adhere strictly to the conditions specified in regulatory labeling to maintain the product's stability.


Required Storage Conditions

Requirement Details
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep all forms away from heat, moisture, and direct light. Liquid solutions must be Kept from freezing.
Packaging Containers, especially for drops, must be kept tightly closed to maintain product integrity and sterility.
Child Safety The medicine must be stored out of the reach of children.

Disposal Instructions

Unused or expired Tisol should be disposed of in the household trash after being mixed with an undesirable substance (such as coffee grounds) and placed in a sealed container. Regulatory guidance advises against introducing the product into the water system by flushing it down the toilet or pouring it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tisol found in:

A-Z Index: